Arcutis Biotherapeutics, Inc. (ARQT): Cost of Revenue
$36.70M
Year ended 2025-12-31
$41.10M
Trailing 12 months to 2026-06-30
+265.1%
3-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $36.70M | +91.8% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $19.13M | +283.6% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $4.99M | +561.4% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $754.0K | n/a | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $0 | n/a | 2024-02-27, From 2021-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $36.70M | +91.8% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $124.03M | -11.8% |
| MannKind Corp (MNKD) | 2025-12-31 | $26.80M | +53.8% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $39.54M | -21.8% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $22.09M | +628.0% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $190.52M | +29.5% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $100.07M | +19.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $132.42M | +2.1% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $10.34M | +33.5% |
Compare ARQT, SVA, MNKD, ARDX side by side · Screen every company in Pharmaceutical Preparations ↗